- Etretinate
-
Etretinate Systematic (IUPAC) name ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate Clinical data AHFS/Drugs.com Micromedex Detailed Consumer Information MedlinePlus a601010 Pregnancy cat. ? Legal status ? Routes Oral Pharmacokinetic data Half-life 120 days Identifiers CAS number 54350-48-0 ATC code D05BB01 PubChem CID 5282375 DrugBank APRD00966 ChemSpider 4445538 UNII 65M2UDR9AG KEGG D00316 ChEBI CHEBI:4913 ChEMBL CHEMBL464 Chemical data Formula C23H30O3 Mol. mass 354.483 g/mol SMILES eMolecules & PubChem (what is this?) (verify)
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It was subsequently removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.
Contents
Properties
Etretinate has a low therapeutic index and a long elimination half-life (t1/2) of 120 days, which make dosing difficult.
Etretinate is an aromatic retinoid, and therefore highly lipophilic. It is stored and released from adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy.
Etretinate has been replaced by acitretin, a safer metabolite of etretinate.
Precautions
- Etretinate is a teratogen, and may cause birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.
- Etretinate should be avoided in children, as it may interfere with bone growth.
- If a patient has ever taken etretinate, he or she is not eligible to donate blood, due to the risk of birth defects.[1]
Side effects
- Hepatitis
- Pseudotumor cerebri
- Diffuse idiopathic skeletal Hyperostosis
References
Antipsoriatics (D05) Topical TarsOtherSystemic PsoralensTrioxysalen • Methoxsalen • BergaptenEtretinate • AcitretinThis dermatologic drug article is a stub. You can help Wikipedia by expanding it.